Breast cancer, colorectal cancer FDA approved Authoritative certification Laos Daxiong Pharmaceutical Tucatinib TUKADX 150mg 60 tablets

Indications:
150mg*60 tablets/box
1. Metastatic breast cancer: combined with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have previously received one or more anti-HER2-based treatment regimens in the metastatic setting. 2. Unresectable or metastatic colorectal cancer: combined with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed after chemotherapy based on fluoropyrimidine, oxaliplatin, and irinotecan.
Recommended dose: {For reference only, follow the doctor's advice}
1. Metastatic breast cancer: The recommended dose is 300 mg orally twice a day, in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity 2. Unresectable or metastatic colorectal cancer: The recommended dose is 300 mg orally twice a day, in combination with trastuzumab until disease progression or unacceptable toxicity. 3. For patients with severe liver damage, take 200 mg orally, twice a day.